FibroGen Statistics

Total Valuation

FibroGen has a market cap or net worth of GBP 39.21 million. The enterprise value is 42.39 million.

Market Cap	39.21M
Enterprise Value	42.39M

Important Dates

The next estimated earnings date is Monday, February 24, 2025.

Earnings Date	Feb 24, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+3.41%
Shares Change (QoQ)	+0.68%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	92.91M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.47
EV / Sales	0.29
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.45

Financial Position

The company has a current ratio of 1.28

Current Ratio	1.28
Quick Ratio	0.98
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.74
Interest Coverage	-6.00

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-20.53%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-161.10%
Revenue Per Employee	276,356
Profits Per Employee	-186,975
Employee Count	486
Asset Turnover	0.50
Inventory Turnover	6.04

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -72.39% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-72.39%
50-Day Moving Average	0.46
200-Day Moving Average	0.67
Relative Strength Index (RSI)	47.66
Average Volume (20 Days)	55,014

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.33

Income Statement

In the last 12 months, FibroGen had revenue of GBP 134.31 million and -90.87 million in losses. Loss per share was -0.91.

Revenue	134.31M
Gross Profit	-11.31M
Operating Income	-88.81M
Pretax Income	-90.97M
Net Income	-90.87M
EBITDA	-85.67M
EBIT	-88.81M
Loss Per Share	-0.91

Full Income Statement

Balance Sheet

The company has 97.74 million in cash and 69.37 million in debt, giving a net cash position of 28.37 million.

Cash & Cash Equivalents	97.74M
Total Debt	69.37M
Net Cash	28.37M
Net Cash Per Share	n/a
Equity (Book Value)	-150.49M
Book Value Per Share	-1.80
Working Capital	40.29M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -93.90 million and capital expenditures -280,534, giving a free cash flow of -94.18 million.

Operating Cash Flow	-93.90M
Capital Expenditures	-280,534
Free Cash Flow	-94.18M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is -8.42%, with operating and profit margins of -66.13% and -67.66%.

Gross Margin	-8.42%
Operating Margin	-66.13%
Pretax Margin	-67.73%
Profit Margin	-67.66%
EBITDA Margin	-63.78%
EBIT Margin	-66.13%
FCF Margin	n/a

Dividends & Yields

FibroGen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.41%
Shareholder Yield	-3.41%
Earnings Yield	-231.73%
FCF Yield	-240.17%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FibroGen has an Altman Z-Score of -10.53. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-10.53
Piotroski F-Score	n/a